Skip to search formSkip to main contentSkip to account menu

GS-5885

Known as: GS 5885, GS5885, WHO 9796 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
ABSTRACT Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved… 
Highly Cited
2014
Highly Cited
2014
A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1… 
Review
2014
Review
2014
Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its… 
Highly Cited
2013
Highly Cited
2013
ABSTRACT GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a… 
2013
2013
ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… 
2012
2012
Background & Aims: GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of…